Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio reported continued investment in its pipeline alongside steady operating losses for the quarter and year ended December 31, 2025. In the fourth quarter, research and development expenses were $25.0 million and general and administrative costs were $6.9 million, leading to a net loss of $30.5 million, or $2.94 per share.
For full-year 2025, R&D spending was $99.1 million and G&A was $23.0 million, resulting in a net loss of $116.8 million, or $16.95 per share. Cash, cash equivalents and short-term investments totaled $158.5 million at year-end, and the company expects this to fund operations into the second half of 2027.
Operationally, Adicet highlighted strong enrollment in its Phase 1 autoimmune trial of prulacabtagene leucel (prula-cel), with clinical updates planned in the first and second halves of 2026, and FDA alignment enabling outpatient dosing for lupus nephritis and systemic lupus erythematosus. A Phase 1 study in treatment-refractory rheumatoid arthritis is underway, with another update expected in the second half of 2026.
The company is also advancing ADI-212 for metastatic castration-resistant prostate cancer, planning a regulatory filing in the third quarter of 2026 and expecting Phase 1 enrollment to begin in the fourth quarter of 2026, subject to regulatory clearance.
Adicet Bio reported an updated ownership filing showing that RA Capital Management and affiliated entities beneficially own 960,237 shares of Adicet Bio common stock. This represents approximately 9.99% of the company’s outstanding shares as of December 31, 2025, just after a 16-for-1 reverse stock split.
The RA Capital Healthcare Fund directly holds 948,249 shares plus pre-funded warrants exercisable for up to 1,152,833 additional shares. However, a “Beneficial Ownership Blocker” in the warrants prevents exercises that would push the group’s stake above 9.99%, so only 11,988 warrant shares are currently counted toward beneficial ownership.
RA Capital serves as investment adviser to the fund and may be deemed a beneficial owner for reporting purposes. The filing states that the securities were not acquired to change or influence control of Adicet Bio and that several reporting persons disclaim beneficial ownership except for meeting disclosure obligations.
Adicet Bio, Inc. shareholder Tang Capital Management and affiliated entities report beneficial ownership of 6,158 common shares, representing about 0.1% of the company’s outstanding common stock. The filing attributes shared voting and dispositive power over these shares to Tang Capital Management, Kevin Tang, and Tang Capital Partners International, LP.
The percentage is based on 9,578,474 Adicet Bio common shares outstanding, after giving effect to a one‑for‑sixteen reverse stock split effective December 30, 2025. The reporting persons certify that the securities are not held for the purpose of changing or influencing control of Adicet Bio.
Woodline Partners LP has disclosed a passive ownership stake in Adicet Bio, Inc., reporting beneficial ownership of 625,000 shares of common stock. This position represents 6.5% of Adicet Bio’s outstanding common shares.
The ownership percentage is based on approximately 9,578,474 shares outstanding, reflecting a 1‑for‑16 reverse stock split effective December 30, 2025. The shares are held by Woodline Master Fund LP, for which Woodline Partners acts as investment adviser, and are certified as being held in the ordinary course of business without the purpose of influencing control of the company.
Adicet Bio, Inc. received a Schedule 13G reporting that investment manager Franklin Advisers, Inc., a subsidiary of Franklin Resources, beneficially owns 626,571 shares of Adicet Bio common stock, representing 6.5% of the outstanding class as of 12/31/2025.
Franklin Advisers is reported to have sole voting and sole dispositive power over these shares. The shares are held in client accounts of Franklin’s investment management subsidiaries, whose clients have the right to receive dividends and sale proceeds. Franklin Resources and its principal shareholders may be deemed beneficial owners under SEC rules but disclaim pecuniary interest and state the holdings are in the ordinary course of business, not to influence control of Adicet Bio.
Adicet Bio's Chief Scientific Officer, Aftab Blake, reported a routine share withholding related to equity compensation. On January 24, 2026, 535 shares of common stock were withheld at $8.44 per share to cover tax obligations arising from the vesting of restricted stock units, and this did not involve an open-market sale. Following this withholding, Blake directly beneficially owned 2,981 shares of Adicet Bio common stock. The reported holdings also reflect a 1-for-16 reverse stock split that Adicet Bio effected on December 30, 2025.
Adicet Bio, Inc.’s Chief Technology Officer Don Healey reported an administrative share adjustment related to equity compensation. On 01/24/2026, 535 shares of common stock were withheld by the company at $8.44 per share to cover tax obligations from vesting restricted stock units, rather than being sold on the market. Following this transaction, Healey beneficially owns 3,452 shares of Adicet Bio common stock on a direct basis. The reported holdings also reflect a previously effected 1-for-16 reverse stock split completed on December 30, 2025, which adjusted the share counts.
Adicet Bio President & CEO Schor Chen reported a routine share withholding related to equity compensation. On January 24, 2026, the company withheld 1,755 shares of common stock at $8.44 per share to cover tax obligations from vesting restricted stock units, which is not a market sale.
After this transaction, Chen reports 6,820 common shares held directly. In addition, 2,716 shares are held indirectly through The I. Schor IRRV Trust and 3,339 shares are held indirectly through The C. Schor IRRV Trust, both irrevocable family trusts with independent trustees. The holdings reflect a previously effected 1-for-16 reverse stock split.
Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units. On January 24, 2026, 546 shares of Adicet Bio common stock were withheld at $8.44 per share to cover tax obligations upon RSU vesting, and this did not involve an open-market sale. After this withholding and giving effect to a 1-for-16 reverse stock split completed on December 30, 2025, he beneficially owned 5,145 common shares directly.
Adicet Bio reported clinical and regulatory progress for its cell therapy programs. Enrollment in its Phase 1 trial of prulacabtagene leucel (prula-cel, formerly ADI-001) in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. The company has also reached alignment with the U.S. Food and Drug Administration to allow patients with lupus nephritis and systemic lupus erythematosus to be dosed with prula-cel in the outpatient setting in ongoing and future trials. Adicet plans to request a meeting with the FDA in the second quarter of 2026 to inform potential Phase 2 pivotal trial design for prula-cel and expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026.